Lipid Involvement in Neurodegenerative Diseases of the Motor System: Insights from Lysosomal Storage Diseases
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Lysosomal storage diseases (LSDs) are a heterogeneous group of rare inherited metabolic diseases that are frequently triggered by the accumulation of lipids inside organelles of the endosomal-autophagic-lysosomal system (EALS). There is now a growing realization that disrupted lysosomal homeostasis (i.e., lysosomal cacostasis) also contributes to more common neurodegenerative disorders such as Parkinson disease (PD). Lipid deposition within the EALS may also participate in the pathogenesis of some additional neurodegenerative diseases of the motor system. Here, I will highlight the lipid abnormalities and clinical manifestations that are common to LSDs and several diseases of the motor system, including amyotrophic lateral sclerosis (ALS), atypical forms of spinal muscular atrophy, Charcot-Marie-Tooth disease (CMT), hereditary spastic paraplegia (HSP), multiple system atrophy (MSA), PD and spinocerebellar ataxia (SCA). Elucidating the underlying basis of intracellular lipid mislocalization as well as its consequences in each of these disorders will likely provide innovative targets for therapeutic research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Bang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144
Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways
Palmieri, M., Impey, S., Kang, H., di Ronza, A., Pelz, C., Sardiello, M., & Ballabio, A. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr306 · Cited by 1,022 · cited 1×
“…that have been identified thus far, more than 70% feature significant central nervous system (CNS) involvement (Wraith, 2004), which is not surprising given that lysosomes recycle cellular debris and they are vital to maintaining cellular homeostasis (Sardiello et al., 2009; Palmieri et al., 2011).”
BackgroundLysosomal disorders: From storage to cellular damage
Ballabio, A., & Gieselmann, V. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.12.001 · Cited by 571 · cited 3×
“However, in most LSDs, more than one compound accumulates, and in some disorders, the stored material is often heterogeneous (Neufeld, 1991; Ballabio and Gieselmann, 2009; Platt et al., 2012).”
BackgroundInoue, K. (2005) · Neurogenetics · doi:10.1007/s10048-004-0207-y · Cited by 285
Braverman, N. E., Raymond, G. V., Rizzo, W. B., Moser, A. B., Wilkinson, M. E., Stone, E. M., Steinberg, S. J., Wangler, M. F., Rush, E. T., Hacia, J. G., et al. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.12.009 · Cited by 281
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
Sardi, S. P., Viel, C., Clarke, J., Treleaven, C. M., Richards, A. M., Park, H., Olszewski, M. A., Dodge, J. C., Marshall, J., Makino, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616152114 · Cited by 203
Self-citationAltered lipid levels provide evidence for myelin dysfunction in multiple system atrophy
Don, A. S., Hsiao, J.-H. T., Bleasel, J. M., Couttas, T. A., Halliday, G. M., & Kim, W. S. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0150-6 · Cited by 88 · cited 3×
“Recent findings suggest that myelin instability in MSA is associated with a significant reduction in GalCer levels (Don et al., 2014).”
Background
Cited by
Hertel, J., Harms, A. C., Heinken, A., Baldini, F., Thinnes, C. C., Glaab, E., Vasco, D. A., Pietzner, M., Stewart, I. D., Wareham, N. J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.035 · Cited by 162
Exploring Sphingolipid Implications in Neurodegeneration
Alessenko, A. V., & Albi, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00437 · Cited by 141
Burg, T., Rossaert, E., Moisse, M., Van Damme, P., & Van Den Bosch, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011224 · Cited by 50
Update review about metabolic myopathies
Finsterer, J. (2020) · Life · doi:10.3390/life10040043 · Cited by 31
“, lysosomal cacostasis) contributes to common neurodegenerative disorders such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS), CMT, hereditary spastic paraplegias (HSPs), or multiple systemic atrophy (MSA) (Table 4) [66].”
Background
Metadata
- Authors
- Dodge, J. C.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-11-03
- Volume
- 10
- Pages
- 356-356
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2765471780
- Cited by
- 32
- References
- 9
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid Involvement in Neurodegenerative Diseases of the Motor System: Insights from Lysosomal Storage Diseases. https://app.cochat.ai/papers/10.3389/fnmol.2017.00356
- The paper
- Dodge, J. C. (2017). Lipid Involvement in Neurodegenerative Diseases of the Motor System: Insights from Lysosomal Storage Diseases. Frontiers in Molecular Neuroscience. https://doi.org/10.3389/fnmol.2017.00356
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.